AtriCure (NASDAQ:ATRC) is one of the most promising mid-cap healthcare stocks under $50. On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC). The analyst assigned a Buy rating and raised her price target on the stock from $42 to $48 per share. According to Lily’s estimates, the stock offers an upside potential of over 17% for investors. gpointstudio/Shutterstock.com AtriCure (NASDAQ:ATRC) recently announced the successful completion of its fir ...